You hear about one peptide on a podcast.
Then another one shows up in your Instagram feed.
Before long, you’re hearing about peptides for gut health, muscle growth, recovery, brain function, libido, sleep, inflammation, immunity, and longevity.
It can feel like a lot.
But here’s the first thing to understand:
Peptides are not one treatment. They’re an entire category of biological messengers.
Some are familiar medications with extensive human research.
Others are emerging therapies supported by smaller human studies.
Some come from fascinating bodies of international research that haven’t received as much attention in mainstream American medicine.
And others are still in the early stages of development.
I’m interested in all of those categories.
The key is knowing which one you’re dealing with.
What exactly is a peptide?
Peptides are short chains of amino acids.
Amino acids are also the building blocks of proteins, but peptides are generally smaller and often act as signaling molecules.
Our bodies naturally make thousands of them.
They help regulate:
- Appetite
- Blood sugar
- Digestion
- Immune activity
- Inflammation
- Growth and repair
- Sexual function
- Blood vessel function
- Brain signaling
- Sleep and circadian rhythm
- Hormonal communication
This is why the phrase peptide therapy covers such a broad range of treatments.
Insulin is a peptide.
GLP-1 receptor agonists are peptide-based medications.
Tesamorelin is a peptide.
Bremelanotide (PT-141) is a peptide.
And then we have compounds such as Semax, Selank, BPC-157, CJC-1295, Epitalon, thymosin alpha-1, and others that are being actively studied, used internationally, or incorporated into emerging areas of clinical practice.
The research behind them varies, but the field itself is on fire.
Peptides are signals
One of the most useful ideas in the work of Dr. William Seeds is the concept that peptides should be understood as signals.
That may sound simple, but it changes the way we think about them.
A peptide isn’t necessarily adding something your body is missing in the way iron replaces iron deficiency.
Instead, many peptides communicate with receptors and pathways that tell cells to change what they’re doing.
For example:
- GLP-1-based therapies influence appetite, glucose regulation, glucagon signaling, and gastric emptying.
- Tesamorelin stimulates growth hormone-releasing hormone receptors.
- Bremelanotide activates melanocortin pathways involved in sexual desire.
- CJC-1295 affects growth hormone and IGF-1 signaling.
Seeds’s broader teaching focuses on understanding the biological pathway before choosing a therapy.
I think that’s a very useful way to think about peptide medicine.
Instead of asking: What peptide should I take?
The better questions are: What am I trying to improve? What biological system is involved? And what other factors are affecting that system?
This is also why more is not always better.
The body works through balance.
Constantly stimulating a pathway isn’t necessarily better than targeted or cyclical use.
Biology is rarely that simple.
What are peptide bioregulators?
This is where the work of Nathalie Niddam adds another interesting layer.
The term peptide bioregulator is most closely associated with the research of Professor Vladimir Khavinson and colleagues.
These compounds are typically very short peptide sequences or tissue-derived peptide preparations that have been studied for tissue-specific regulatory effects.
Niddam often describes bioregulators as working at a more targeted tissue level, influencing how certain cells function and possibly affecting gene expression and cellular regulation.
The bioregulator field includes compounds associated with tissues such as:
- Pineal gland
- Thymus
- Blood vessels
- Brain
- Liver
- Pancreas
- Thyroid
- Reproductive organs
One concept Niddam frequently discusses is using these compounds in cycles rather than assuming that every therapy must be taken indefinitely.
I find that idea interesting because it fits with the broader concept of signaling.
The goal may be to influence a biological process and then reassess rather than simply staying on something forever.
There are important nuances here.
For example, Epithalamin and Epitalon are related but not identical.
Epithalamin is a peptide preparation derived from bovine pineal tissue.
Epitalon is a specific synthetic tetrapeptide derived from epithalamin.
That distinction matters when we look at the research.
Older human studies of pineal and thymic peptide preparations reported intriguing findings related to aging, immune function, and mortality.
I think this body of work deserves more attention, not less.
At the same time, we should be careful to match claims to the exact compound and formulation that was actually studied.
That isn’t negativity.
That’s how we protect promising science from being oversold.
The peptide is part of the therapy
One of the most practical ideas I’ve heard repeated in peptide education is:
The peptide is part of the therapy.
I strongly agree with that.
A peptide may be helpful.
But it still lives inside the biology of the person using it.
That means:
- Sleep matters.
- Protein intake matters.
- Resistance training matters.
- Blood sugar regulation matters.
- Hormonal status matters.
- Nutrient status matters.
- Stress matters.
- Gut health matters.
A peptide may influence signaling, recovery, inflammation, or repair.
But it is not a substitute for understanding what is happening in the body and dialing in a strong foundation first.
That’s true whether we’re talking about hormones, supplements, or peptides.
Which peptides have the strongest human evidence?
It helps to think of peptide research as a continuum rather than dividing everything into proven and unproven.
Some therapies have large clinical development programs.
Others have smaller but meaningful human studies.
Others have promising mechanistic and preclinical evidence and are earlier in development.
Let’s look at a few examples.
GLP-1-based medications
These are the best-known peptide-based therapies right now.
GLP-1 medications have extensive human evidence in diabetes and obesity, and several products have also demonstrated cardiovascular and other health benefits in specific populations.
They are a good reminder that peptide medicine is not fringe medicine.
Peptide-based therapies can become mainstream when enough clinical data accumulate.
And I suspect we’ll see more examples of that in the future.
Tesamorelin
Tesamorelin is a growth hormone-releasing hormone analog.
It has randomized human trial data showing reductions in visceral abdominal fat in adults with HIV-associated lipodystrophy.
That doesn’t mean it should be used in everyone with abdominal fat.
But the research demonstrates that the peptide can create meaningful changes in body composition in humans.
That makes it an important compound to watch as research continues.
Bremelanotide
Bremelanotide, also known as PT-141, activates melanocortin receptors and has human trial data supporting its use in certain premenopausal women with acquired, generalized hypoactive sexual desire disorder.
What interests me about this peptide is that it approaches sexual function through central nervous system signaling rather than primarily through hormone replacement or blood flow.
That opens up another way of thinking about sexual health.
And it reminds us that low libido in women is complex.
Hormones matter.
Sleep matters.
Relationships matter.
Pain matters.
Medications matter.
Brain signaling matters too.
Thymosin alpha-1
Thymosin alpha-1 is one of the more extensively studied immune-related peptides.
It has been studied internationally in areas including infection, immune dysfunction, cancer support, and critical illness.
The research is mixed depending on the condition, which is exactly what we would expect from a biologically active therapy used across very different patient populations.
For example, a large phase 3 study in sepsis did not show a clear reduction in short-term mortality.
That doesn’t erase the broader body of work.
It tells us that indication is important.
Immune support is a very broad phrase.
The more useful questions are:
- Which patient?
- Which condition?
- Which outcome?
- Which dose?
- Which stage of illness?
Those are the questions that move medicine forward.
Semax
Semax has human research dating back years, particularly in Russia and Eastern Europe.
Much of the work has focused on neurological conditions, stroke recovery, cognitive function, and neurotrophic signaling.
A study involving people recovering from ischemic stroke reported improvements in functional measures and changes in BDNF, a protein involved in neuroplasticity.
I think Semax is a good example of a peptide that deserves continued research and broader scientific attention.
The mistake would be either to dismiss the existing research because it wasn’t conducted in the United States or to take a promising neurological study and assume the same outcomes apply to everyone who wants a cognitive boost.
The sensible position is in the middle.
Interesting human evidence.
Promising mechanisms.
Further research needed.
Selank
Selank also has human research, much of it originating in Russia.
It has been studied for anxiety-related conditions and has shown anxiolytic effects in small human trials.
Again, I think this research is worth paying attention to.
Small studies can be important.
Many treatments begin with small studies.
The key is continuing to build the evidence base rather than labeling early evidence as either meaningless or definitive.
Want to create a custom longevity health plan?
You’re in the right place.
I can help you with a functional approach to midlife women’s health including hormone balance, gut health, autoimmune issues, bone health, heart health and more!
Peptide bioregulators and healthy aging
Some of the most fascinating peptide research comes from the long-term work on pineal and thymic peptide preparations.
Studies involving older adults reported encouraging findings related to immune function, illness rates, markers associated with aging, and mortality.
This research is one reason peptide bioregulators have generated so much interest in longevity circles.
I think the work is genuinely intriguing.
I also think it creates an important research opportunity.
We need larger independent studies using clearly characterized compounds and modern study design.
That would help answer an important question:
Can targeted short peptides meaningfully influence aging biology in humans?
I don’t think we know the full answer yet.
But I think it’s a question worth pursuing.
BPC-157
BPC-157 is probably one of the most talked-about peptides in regenerative medicine.
Its preclinical research is impressive in scope.
Animal studies have explored effects involving:
- Tendons
- Ligaments
- Muscle
- Nerves
- Blood vessels
- Gastrointestinal tissue
- Inflammatory signaling
Human data are much smaller, but they do exist.
A small report involving people receiving intra-articular BPC-157 for knee pain reported improvement in a number of participants.
A more recent small IV safety study also adds to the early human literature.
Neither study answers every question.
This is what early clinical development often looks like.
We start with mechanism. Then animal research. Then small human reports. Then safety work. Then larger controlled studies.
BPC-157 is somewhere in that progression.
I think we need to be aware that the size of the evidence base in this case doesn’t yet match the size of its popularity.
CJC-1295 and growth hormone signaling
CJC-1295 has human research showing that it can produce sustained increases in growth hormone and IGF-1 so we know it has biological activity.
But what about clinical outcomes?
Does this activity translate into improvements in:
- Body composition?
- Recovery?
- Sleep?
- Strength?
- Function?
- Healthy aging?
Those are the questions that future trials need to answer.
This is where Dr. Seeds’s mechanism-based framework is especially useful.
Understanding the pathway is the beginning of the conversation.
Then we ask whether influencing that pathway creates meaningful benefits in the right person.
Thymosin beta-4 and TB-500
This area requires careful terminology.
Full-length thymosin beta-4 has been studied in humans in certain settings.
TB-500, as commonly marketed, is associated with a fragment of thymosin beta-4 and should not automatically be treated as identical to the full-length molecule.
Niddam has discussed this distinction in her peptide education, and it’s an important one.
Similar names do not guarantee identical biological effects.
Still, the broader thymosin beta-4 research is interesting because of the peptide’s potential role in tissue repair, cell migration, angiogenesis, and recovery.
This is another area I’ll be watching.
MOTS-c
MOTS-c is a mitochondrial-derived peptide that has generated significant interest in metabolic health and aging research. MOTS-c is a 16-amino-acid mitochondrial-derived peptide (MDP) encoded by the mitochondrial DNA that acts as a systemic regulator of metabolism. By activating AMPK, it enhances cellular energy utilization, improves insulin sensitivity, and promotes metabolic stress adaptation. Preclinical data show it may protect against diet-induced obesity and age-related insulin resistance.
Animal models and pilot human data indicate significant potential in improving glucose metabolism. A recent 2026 pilot dataset reported a 44% reduction in insulin resistance (HOMA-IR) compared to metformin’s 17%.
Could all the people already using peptides become part of the evidence?
I think this is one of the most important questions in the peptide conversation.
There are already large numbers of people using peptides in real-world clinical practice.
Some are using them for injury recovery.
Others are using them for body composition, sleep, cognition, immune function, gut health, sexual function, or healthy aging.
Does their experience count for nothing simply because they weren’t enrolled in a randomized controlled trial?
I don’t think so.
Medicine increasingly recognizes the importance of real-world evidence.
Information collected through medical records, patient registries, wearable devices, laboratory testing, and patient-reported outcomes can help us understand how a therapy performs outside the carefully controlled environment of a traditional clinical trial.
This could be incredibly valuable in peptide medicine.
Imagine a well-designed prospective registry in which people starting BPC-157 or other peptides were followed from the beginning.
Researchers could collect:
- The exact diagnosis or reason for treatment
- Age and relevant health history
- The exact product and source
- Dose, route, and duration
- Other treatments being used at the same time
- Baseline pain and function scores
- Imaging when appropriate
- Standardized follow-up measurements
- Adverse events
- Reasons for discontinuation
- Outcomes at three, six, and 12 months
Now imagine doing that with several thousand people.
That would be far more informative than hundreds of social media posts saying, “It worked for me.”
It still wouldn’t answer every question. Observational research has limitations, and well-designed randomized trials remain important.
But we shouldn’t pretend that the only useful knowledge comes from a traditional pharmaceutical development program.
Real-world experience can help identify patterns, potential benefits, adverse effects, responder characteristics, and important questions for future trials.
In my opinion, the peptide field needs more organized data collection, not dismissal of the people who are already using these therapies.
There is a tremendous difference between anecdote and systematically collected real-world evidence.
The peptide community has plenty of the first.
It is time to create more of the second.
What should you ask before using a peptide?
I don’t think the right question is: Are peptides good or bad?
That’s far too broad.
A better set of questions is:
- What problem am I trying to solve?
- What pathway are we trying to influence?
- What is the exact molecule?
- What human evidence exists?
- Was it studied for my goal?
- What outcomes improved?
- What is known about safety?
- What will be monitored?
- How long is therapy expected to continue?
- Will it be cycled?
- How will we know whether it’s helping?
- Where is the product coming from?
Those questions don’t close the door on emerging therapy. They help you walk through the door intelligently.
Sourcing matters more than most people realize
This is the area where I am not flexible.
I would not recommend buying injectable peptides from gray-market websites selling products labeled:
For research use only | Not for human consumption
The reason isn’t that I think the molecules themselves are necessarily bad.
The problem is that you may not know what is actually in the vial.
With an injectable product, you need confidence in:
- Identity
- Purity
- Concentration
- Sterility
- Storage
- Shipping conditions
- Contaminant testing
- Endotoxin testing
- Product stability
Anyone can create a beautiful website and certificate of analysis.
There is also an important distinction between legitimate pharmacy compounding and gray-market research chemicals.
Compounded medications are not FDA-approved, but appropriate quality controls and reputable raw material sourcing are in place. Regulated pharmacy compounding is fundamentally different from buying an injectable research chemical directly from an anonymous website.
This is one of the reasons I believe peptide therapy should involve appropriate clinical oversight.
Not because we should be afraid of emerging medicine, but because we want emerging medicine to be done well, for people to get the results they want and to be safe in the process.
My bottom line on peptides
I’m genuinely excited about peptide medicine.
Some peptide therapies are already firmly established.
Others have meaningful human evidence that deserves more attention.
Some of the international research, especially around compounds such as Semax, Selank, thymic peptides, and peptide bioregulators, deserves a more thoughtful look than it often receives.
Other compounds are earlier in the research process but have enough biological plausibility and preclinical evidence to justify continued investigation.
I don’t think the answer is to dismiss peptides.
And I don’t think the answer is to treat every exciting molecule like it has already been proven to do everything claimed online.
The right approach is more interesting than either extreme.
- Understand the biology.
- Look at the human data that exist.
- Respect promising early evidence.
- Pay attention to the exact molecule and formulation studied.
- Use appropriate monitoring.
- Reassess.
- Source products through legitimate channels.
Peptide medicine is evolving quickly.
I suspect we are still in the early chapters.
And I’m very interested to see what comes next.
If you’re trying to sort through conflicting information about hormones, gut health, metabolism, healthy aging, or emerging therapies, let’s talk.
Frequently Asked Questions About Peptides
Are peptides new?
No. The body naturally produces peptides, and peptide-based medications have been used for decades. What is newer is the growing interest in using specific peptides for regenerative medicine, brain health, immune function, metabolic health, and healthy aging.
Do peptides have human research?
Yes. The amount varies widely by peptide. Some have extensive randomized clinical trials. Others have smaller human studies, including research from outside the United States. Others remain primarily supported by animal and laboratory research.
Is international peptide research valid?
Research should be judged by study design, population, methodology, replication, and relevance, not simply by country of origin. Some important peptide research comes from Russia, Eastern Europe, China, and other regions.
What is a peptide bioregulator?
Peptide bioregulators are typically very short peptide sequences or tissue-derived peptide preparations proposed to influence tissue-specific cellular regulation and gene expression.
Is BPC-157 proven?
BPC-157 has extensive preclinical research and a small amount of human data. The field is promising, but larger controlled human studies are still needed to better define effectiveness, dosing, and long-term safety.
Should peptides always be used continuously?
Not necessarily. Some clinicians and peptide educators use cyclical approaches depending on the peptide and goal. The ideal duration and cycling strategy vary by compound and aren’t equally well established for every therapy.
How should I choose a peptide provider?
Look for someone who can explain why the peptide is being recommended, what evidence exists, where the product comes from, what will be monitored, how long treatment is expected to continue, and what would cause the treatment plan to change. Be cautious of providers who offer large stacks without a clear biological rationale.
References
Falutz, J., Potvin, D., Mamputu, J. C., Assaad, H., Zoltowska, M., Michaud, S. E., et al. (2010). Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: A randomized placebo-controlled trial with a safety extension. Journal of Acquired Immune Deficiency Syndromes, 53(3), 311–322.
Gusev, E. I., Martynov, M. Y., Kostenko, E. V., Petrova, L. V., & Bobyreva, S. N. (2018). The efficacy of Semax in the treatment of patients at different stages of ischemic stroke. Zhurnal Nevrologii i Psikhiatrii Imeni S. S. Korsakova, 118(3, Suppl. 2), 61–68.
Khavinson, V. K., & Morozov, V. G. (2003). Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters, 24(3–4), 233–240.
Korkushko, O. V., Khavinson, V. K., Shatilo, V. B., & Antonyuk-Shcheglova, I. A. (2006). Geroprotective effect of epithalamine in elderly subjects with accelerated aging. Bulletin of Experimental Biology and Medicine, 142(3), 356–359.
Lee, E., & Burgess, K. (2025). Safety of intravenous infusion of BPC157 in humans: A pilot study. Alternative Therapies in Health and Medicine, 31(5), 20–24.
Lee, E., & Padgett, B. (2021). Intra-articular injection of BPC 157 for multiple types of knee pain. Alternative Therapies in Health and Medicine, 27(4), 8–13.
Niddam, N. (2023). The basics of peptides [Podcast episode]. LONGEVITY with Nathalie Niddam.
Niddam, N. (2024). The ultimate intro to bioregulator peptides [Podcast episode]. LONGEVITY with Nathalie Niddam.
Seeds, W. A. (2020). Peptide protocols: An introduction to what peptides are, how and why they work, and how they can be used to improve health and outcomes. Seeds Scientific Research & Performance.
Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of growth hormone-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805.
Wu, J., Pei, F., Zhou, L., et al. (2025). The efficacy and safety of thymosin α1 for sepsis: Multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ, 388, e082583.
Zozulia, A. A., Neznamov, G. G., Siuniakov, T. S., et al. (2008). Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia. Zhurnal Nevrologii i Psikhiatrii Imeni S. S. Korsakova, 108(4), 38–48.
Dr. Anna Garrett is a menopause expert and Doctor of Pharmacy. She helps women who are struggling with symptoms of perimenopause and menopause find natural hormone balancing solutions so they can rock their mojo through midlife and beyond. Dr. Anna is the author of Perimenopause: The Savvy Sister’s Guide to Hormone Harmony. Order your copy at www.perimenopausebook.com.
Dr. Anna is available for 1-1 consultations. Find out more at www.drannagarrett.com/lets-
